Study Finds Lower-Cost Rituximab as Effective as Ocrelizumab for MS Treatment

A new clinical trial published in The New England Journal of Medicine indicates that rituximab, a more affordable B-cell depleting therapy, is as effective as the higher-cost ocrelizumab for treating newly diagnosed relapsing multiple sclerosis. This discovery could significantly improve global access to treatment and enhance healthcare sustainability by offering a cost-effective alternative.